This Development of Islet-Targeted Drug Delivery Strategies in T1D Grant is offered by the Juvenile Diabetes Research Foundation (JDRF) to researchers focused on halting the progression of T1D and achieving a cure through the development of disease-modifying therapies that promote the survival, function, and regeneration of endogenous insulin-producing beta cells.
Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent. Applicants must also have a faculty position or equivalent at a college, university, medical school, or other research facility. There are no citizenship requirements. This grant offers up to $900,000.00 USD for three years. Applications submitted via JDRF’s Strategic Research Agreement (SRA) can include up to 10% indirect costs. If submitted to Industry Discovery and Development Program (IDDP), applications do not permit indirect costs. Letters of intent are due on August 17, 2022. Full applications must be submitted by October 5, 2022.
